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Abstract
Background: Protein tyrosine phosphatases (PTPs) are important cell signaling regulators with major pathological
implications. LYP (also known as PTPN22) is an intracellular enzyme initially found to be predominately expressed
in lymphocytes. Importantly, an allelic R620W variant of LYP is strongly associated with multiple autoimmune
diseases, including systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, and autoimmune thyroid
disease.
Results: In this study, we isolated a novel isoform of LYP designated LYP3. LYP3 differs from LYP1, the known
isoform of LYP, in that it lacks a 28 amino acid segment right after the R620W site embedded in a proline-rich
protein-protein interaction motif. Genomic sequence analysis revealed that LYP3 resulted from alternative splicing
of the LYP gene located on chromosome 1p 13.3-13.1. Reverse transcription PCR analyses of 48 human tissues
demonstrated that both LYP1 and LYP3 are predominantly expressed in primary and secondary lymphoid tissues
but the relative expression levels of the two isoforms varies in different human tissues and individuals.
Conclusions: We thus identified a new variant form of LYP and conducted a comprehensive analysis of LYP tissue
expressions. Considering the pathogenesis of LYP R620W, we believe that the expression of LYP3 may have an
important role in regulating activity and function of LYP and may be implicated in autoimmune diseases.
Background
Protein tyrosine phosphatases (PTPs) act in a coordi-
nated manner with protein tyrosine kinases to control
cell signaling thereby regulating various physiological
processes [1]. Malfunctioning of these enzymes has
major pathological implications. One of the best known
examples is the allelic variant of the lymphoid tyrosine
phosphatase LYP (PTPN22) which is associated with
multiple autoimmune diseases, including systemic lupus
erythematosus, rheumatoid arthritis, type 1 diabetes, and
autoimmune thyroid disease [2,3].
LYP is a cytoplasmic enzyme belonging to the PEST
group of non-receptor classical PTPs [4]. It contains 807
amino acid residues. The murine ortholog of LYP is
called PEP [5]. LYP and PEP share 89% and 61%
sequence identity in their PTP domains and noncatalytic
portions, respectively. The N-terminal part of LYP/PEP
contains the catalytic domain conserved in all classical
PTPs. The structure of the sequence following the cata-
lytic domain is largely undefined. The last 200 amino
acid segment contains 4 proline-rich sequence motifs
(P1-P4) which presumably provides docking sites for
SH3 domain-containing signaling proteins. The first of
these motifs, P1, is known to bind with relatively high
stoichiometry to the SH3 domain of the Csk tyrosine
kinase, an important negative regulator of T-cell antigen
receptor signaling [6-8]. LYP/PEP and Csk appear to
have complementary functions. While Csk phosphory-
lates the negative regulatory tyrosine residue at the
C-terminal end of Lck and Fyn, LYP/PEP dephosphory-
lates the positive regulatory site in the middle of these
two tyrosine kinases [9]. Both actions result in inhibition
of TCR signaling. LYP/PEP also negatively regulates T
cell signaling by dephosphorylating Zap-70 and the tyro-
syl residues within the immunoreceptor tyrosine-based
activation motifs in CD3 ζ-chains, which are phosphory-
lated by Src family tyrosine kinases [10]. Further studies
by using a substrate-trapping mutant of LYP in combi-
nation with mass spectrometry identified the following
substrates: Lck (at Y394), ZAP-70 (at Y493), Vav,
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sine-based activation motifs in CD3 ζ-chains [11]. LYP/
PEP is predominately expressed in lymphocytes, and it
is generally defined as a key inhibitor of T-cell
activation.
A major advancement in the study of LYP is the find-
ing of a single nucleotide polymorphism (SNP), namely,
C1858T, which generates an R620W amino acid substi-
tution (reviewed in 2, 3). This SNP is a common risk
factor for many autoimmune diseases, including type I
diabetes [12], systemic lupus erythematosus [13], rheu-
matoid arthritis [14,15], and Graves’ disease [16]. The
620 amino acid residue is located within the first pro-
tein-rich motif P1, which interacts with the SH3 domain
of Csk [6-8]. The R620W amino acid substitution pre-
sumably interrupts the interaction of P1 with the SH3
domain of Csk [12]. However, a later study revealed that
the R620W substitution is actually a gain-of-function
mutation that generates a more active PTP that acts as
a more effective inhibitor of T-cell signaling than the
w i l d - t y p ee n z y m e[ 1 7 ] .T h em e c h a n i s mb yw h i c ht h i s
R620W substitution in the non-catalytic segment leads
to activation of the phosphatase remains to be defined.
It was postulated that this activating mutation in LYP
m a yc a u s eap r e d i s p o s i t i o nt oa u t o i m m u n ed i s e a s e
either by failure to delete auto-reactive T cells or due to
insufficient activity of regulatory T cells [17]. In any
event, the C-terminal part of LYP has a crucial role in
regulating the catalytic activity of LYP and its physiolo-
gical functions. In this study, we isolated a new variant
form of LYP designated LYP3 which differs from LYP1,
the known isoform of LYP, in the C-terminal region
right after the R620W substitution site. We found that
the expression level of LYP3 relative to LYP1 varies in
different tissues and among different individuals.
Methods
Materials
Total RNAs were isolated from de-identified human
peripheral blood samples by using the Trizol reagent
(Invitrogen) and were then treated with RQ1 RNase-free
DNase (Promega) to remove contaminated genomic
DNAs. First-strand cDNA was synthesized by using the
iScript cDNA Synthesis Kit (Bio-Rad) with random pri-
mers. Human Major Tissue qPCR Array containing first
strand DNAs from 48 tissues was purchased from
OriGene.
Molecular cloning of LYP
Based on the coding sequence of LYP in GenBank data-
base, two PCR primers, namely, Lyp5’ (5’-GACATGCCC
TCCCTCAACCTACTTA) and Lyp3’ (5’-TGCAGGTG-
TACTTGCAGCCCATATTA) were synthesized. They
correspond to the 5’ and 3’ ends of the coding sequence of
LYP1, respectively. Single-strand cDNAs synthesized with
total RNAs purified from human peripheral blood samples
were used as templates. The PCR was run for 35 cycles
with Phusion polymerase (Finnzymes) at 94°C for 30 sec,
65°C for 30 sec, and 72°C for 2 min. The PCR products
were ligated with T4 DNA ligase into the pBluescript KS
vector which was opened by digestion with EcoRV. Clones
were selected based on blue-white selection, and plasmid
DNAs were isolated for sequencing analyses with T3 and
T7 primers by using the automatic DNA sequencing facil-
ity at the Oklahoma Medical Research Foundation.
Determination of tissue distributions of LYP1,
LYP2, and LYP3
To determine the expression of LYP1, LYP2, and LYP3 in
various human tissues, we employed the Human Major
Tissue qPCR Array (OriGene) containing first strand
DNAs from 48 tissues. The PCR primers were L1 (5’-
CTAGCAACTGCTCCAAGGATAGATGA), L1r (5’-GC
TTGTTTGGTGGGCAAGAATTACA), L2r (5’-GGGCT
AAATGTCATCTAAAGCCAAG), and L2 (5’- TCCTCA
GCTGTGAAGAGTGTAAAACTC). These primers were
d e r i v e df r o md i f f e r e n te x o n so nt h eL Y Pg e n ea n da r e
expected to give rise to distinct PCR products for LYP1,
LYP2, and LYP3 cDNAs. L1 and L1r produce 505 and 421
bp fragments from LYP1 and LYP3, respectively; L1 and
L2r amplify a 284 bp fragment from LYP2 only; L2 and
L1r specifically yield a 301 bp fragment of LYP3. The PCR
was run for 35-45 cycles, and the conditions were 94°C for
20 sec, 63°C for 20 sec, and 72°C for 1 min. The products
were analyzed on 1.5% agarose gels stained with ethidium
bromide or on 8% acrylamide gels visualized by using sil-
ver staining.
Results and Discussion
Identification of LYP3, a variant form of LYP
In order to clone the full-length form of LYP1, we
designed a pair of primers that cover the entire coding
sequence of LYP1 (GenBank accession no. NM_015967).
Single-strand cDNAs from a human peripheral blood
sample were used as templates for PCR, and the PCR
products were cloned into the pBluescript KS vector.
Interestingly, DNA sequencing analyses revealed clones
carrying the expected LYP1 but also a variant form of
LYP which is 84 bp shorter in cDNA corresponding to
a 28 amino acid deletion. Since there is a variant form
of LYP2 in the GenBank database (NM_012411), we
designate the new isoform LYP3. The DNA sequence of
LYP3 has been deposited in the GenBank database
under accession no. GU479452. Figure 1 shows a
sequence alignment of amino acid residues of the three
forms of LYP at the C-terminal regions where these
three isoforms differ. LYP1 contains an N-terminal PTP
domain, a central region of unknown function, and a
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containing four proline-rich motifs termed P1-P4. P4 is
part of the so-called C-terminal homology (CTH)
domain, which is found in all members of the PEST
group of PTPs [1,2]. LYP3 differs from LYP1 in that it
is missing 28 amino acid residues in between the P1
and P2 region. P1 is known to interact with the SH3
domain of the Csk tyrosine kinase, an important nega-
tive regulator of T-cell antigen receptor signaling [6-8].
Shortening of the P1-P2 linker region may affect the
CSK/LYP interaction and other unidentified interactions.
It should be noted that the C1858T SNP happens to
cause the R620W substitution in the P1 region. In addi-
tion, LYP2, another variant form of LYP, has an even
shorter C terminus lacking P2, P3, and P4.
LYP3 is an alternative splicing product
A search of the human genome database by using the
BLAST program revealed that LYP3 is a result of alter-
native RNA splicing. Both LYP1 and LYP3 consist of 21
exons with the translation initiation and termination
codons residing in the first and last exons, respectively.
All the intron-exon junctions follow the GT-AG rule.
LYP1 and LYP3 differ in exon 15 where LYP3 is 84 bp
shorter. Figure 2 also shows the exon-intron structure
of LYP2. LYP2 has a longer exon 16 which contains an
in-frame termination codon. To verify the presence of
LYP3, we designed primers L1 and L1r that amplify
both LYP1 and LYP3. PCR results demonstrated the
presence of the shorter LYP3 product in blood samples
(Figure 3A). Interestingly, the relative ratios of LYP1
and LYP3 appeared to differ among samples from differ-
ent individuals. DNA sequencing analyses of gel-purified
PCR products confirmed that the shorter product
indeed corresponded to LYP3 which is 84 bp shorter
than the longer LYP1 PCR product (Figure 3B,C). We
also employed a pair of primers (L2 and L1r) to amplify
LYP3 specifically. Data in Figure 3D illustrated a single
band of expected size for all 11 blood samples. These
blood samples analyzed here were collected from var-
ious de-identified normal volunteers and patients. We
do not yet know if these differential expressions of
LYP1 and LYP3 correlate with any disease phenotype.
Distribution of three isoforms of LYP in human tissues
As its name indicates, LYP was initially thought to be
expressed specifically in lymphocytes. This was based on
the Northern blotting analyses of a limited number of
human tissues (spleen, thymus, prostate, ovary, testis,
small intestine, and colon) and cell lines [4]. However,
subsequent studies revealed expression of LYP in normal
granulocytes and monocytes and a number of myeloid cell
lines [18]. We felt that it was necessary to conduct a more
comprehensive analysis of LYP expression. For this pur-
pose, we employed the human Major Tissue qPCR Array
from OriGene. The array contains the first strand cDNAs
of 48 human tissues. The cDNAs have been normalized
with house keeping genes, and thus PCR data represent
Figure 1 Sequence alignment of three isoforms of LYP at the C-terminal region starting from amino acid residue No. 571.T h ef o u r
proline-rich motifs are underlined. The pathogenic R620W substitution is shown in bold and indicated by an arrow.
Figure 2 Schematic diagram of the gene structure of three isoforms of LYP. Exons are represented by bars and drawn approximately
proportional to their sizes and positions. The open part of bars stands for non-translational regions. The numbers of exons are selectively labeled
based on the LYP1 coding sequence. Note that LYP3 has a short exon 15 and LYP2 contains a longer exon 16 with an in-frame stop codon. All
the intron-exon junctions follow the GT-AG rule.
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tissues. We first performed PCR with primers that cover
both LYP1 and LYP3. The data shown in the upper four
panels of Figure 4 demonstrate that both LYP1 and LYP3
are highly expressed in major lymphoid tissues (bone mar-
row, lymph node, peripheral blood, spleen, and thymus).
They are also expressed at a high level in lung and fat and
at lower levels in many other tissues including adrenal
gland, colon, duodenum, intestine, intracranial artery,
pituitary, rectum, skin, stomach, testis, tonsil, ureter, urin-
ary bladder, and uterus. These tissues can be considered
as the mucosa-associated lymphoid system which contains
small concentrations of diffuse lymphoid cells. However, it
is hard to attribute all the expression of the LYP isoforms
to the presence of lymphocytes in lung and fat considering
the level of expression. Further immunohistochemical
Figure 3 PCR amplification of LYP1 and LYP3 and verification of PCR products by DNA sequencing. A. Single-strand cDNAs obtained
from peripheral blood of 11 individuals were amplified with primers L1and L1r which give rise to both LYP1 and LYP3. PCR products were
resolved on 1.5% agarose gels and were detected by staining with ethidium bromide. B. and C. LYP1 and LYP3 PCR products shown in panel A
above were purified by using 8% polyacrylamide gel and re-amplified with primers L1 and L1r for sequencing analyses with primer L1. Note that
underlined sequence of LYP1 in panel B denotes the 84 bp segment missing in LYP3. The sequencing data represent all LYP1 and LYP3 bands
shown in Fig. 3A and Fig. 4. D. LYP3 was amplified from the 11 blood cDNA samples shown above in panel A with primers L2 and L1r. PCR
products were resolved on 1.5% agarose gels and were detected by staining with ethidium bromide.
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in non-lymphocytes. Nonetheless, it is clear from our data
that LYP1 and LYP3 are not expressed in major non-lym-
phoid tissues such as brain, heart, liver, and muscle. LYP1
appears to be the major form in most of the lymphoid tis-
sues, and the ratios between LYP1 and LYP3 vary in differ-
ent tissues. Interestingly, however, the retina only
expresses LYP3. It is also worth noting that LYP3 is not
present in the lung. Overall, our data generally support the
notion that LYP1 and LYP3 are expressed in primary and
secondary lymphoid tissues. We also synthesized PCR pri-
mers to amplify specifically the reported LYP2 isoform.
LYP2 was initially cloned from a human thymocyte library
[4]. It contains a shorter C terminus due to the presence
Figure 4 Distribution of three isoforms of LYP in 48 human tissues. First-strand cDNAs in the Human Major Tissue qPCR Array kit (OriGene)
were amplified by PCR with primers L1/L1r for LYP1 and LYP3 and L1/L2r for LYP2 as described in Materials and Methods. PCR products were
resolved on 8% polyacrylamide gel and were detected with silver staining. The expected LYP1, LYP2, and LYP3 PCR products are indicated. For
simplicity, only selected data were shown for analysis of LYP2.
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and 2). However, no further follow up work was done.
Our data indicate that LYP2 indeed exists, but only at very
low levels in peripheral blood lymphocytes, thymus, and
interestingly in prostate (Figure 4, two lower panels).
DNA sequence variations play a fundamental role in
human phenotypic variability, including susceptibility to
diseases. SNPs represent the most extensively studied
sequence variations. Non-synonymous SNPs change the
amino acid sequence and presumably alter protein func-
tions. The C1858T SNP that leads to the R620W substi-
tution in LYP is a typical example. On the other hand,
alternative splicing of mRNA may generate protein iso-
forms of different sizes with different biological proper-
ties such as protein/protein interaction, subcellular
localization, and catalytic activity [19,20]. We believe
that this should be the case for LYP2 and LYP3. To
ensure correct cellular functions, gene expression is
finely regulated both spatially and temporally, and the
importance of aberrant RNA processing in diseases has
been generally recognized. Pre-mRNA splicing is a
tightly regulated process affected by many factors
including SNPs [21]. In this regard, it should not be a
surprise if the C1858T SNP affects expression of alter-
native spliced forms of LYP. The C1858T SNP is pre-
sent mainly in Caucasian populations and is essentially
absent in African and Asian populations [2]. It is not
known if other DNA variations in LYP affect autoim-
mune diseases in the latter populations which have no
fewer incidences of these diseases. Our data indicate
that the relative ratios of LYP isoforms vary among dif-
ferent individuals. It will be important to find if aberrant
expression of LYP isoforms cause any human diseases,
particularly autoimmune diseases.
Conclusions
To conclude, extensive literatures exist to support the
association between LYP and multiple autoimmune dis-
eases. However, the underlying molecular mechanism is
still elusive. We have now identified a novel isoform of
LYP designated as LYP3. This allows us to look at the
problem from a new angle.
Acknowledgements
This work was supported by grants HL079441 and HL094591 from the
National Institutes of Health, a grant from Oklahoma Center for the
Advancement of Science & Technology, and a Boyou fund from China
Soong Ching Ling Foundation (to ZJ Zhao).
Author details
1Department of Pathology, University of Oklahoma Health Sciences Center,
Oklahoma City, Oklahoma 73104, USA.
2Edmond H. Fischer Signal
Transduction Laboratory, College of Life Sciences.
3School of Pharmaceutical
Sciences, Jilin University, Changchun, PR China.
Authors’ contributions
SW, HD, JH, and WTH conducted the research experiments; XF designed the
experiments; ZJZ designed the experiments and wrote the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 July 2010 Accepted: 2 November 2010
Published: 2 November 2010
References
1. Tonks NK: Protein tyrosine phosphatases: from genes, to function, to
disease. Nat Rev Mol Cell Biol 2006, 7:833-846.
2. Vang T, Miletic AV, Arimura Y, Tautz L, Rickert RC, Mustelin T: Protein
tyrosine phosphatases in autoimmunity. Annu Rev Immunol 2008,
26:29-55.
3. Chung SA, Criswell LA: PTPN22: its role in SLE and autoimmunity,
Autoimmunity. 2007, 40:582-590.
4. Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM: Cloning and
characterization of a lymphoid-specific, inducible human protein
tyrosine phosphatase, Lyp. Blood 1999, 93:2013-2024.
5. Matthews RJ, Bowne DB, Flores E, Thomas ML: Characterization of
hematopoietic intracellular protein tyrosine phosphatases: description of
a phosphatase containing an SH2 domain and another enriched in
proline-, glutamic acid-, serine-, and threonine-rich sequences. Mol Cell
Biol 1992, 12:2396-2405.
6. Cloutier JF, Veillette A: Association of inhibitory tyrosine protein kinase
p50csk with protein tyrosine phosphatase PEP in T cells and other
hemopoietic cells. EMBO J 1996, 15:4909-4918.
7. Gregorieff A, Cloutier JF, Veillette A: Sequence requirements for
association of protein-tyrosine phosphatase PEP with the Src homology
3 domain of inhibitory tyrosine protein kinase p50(csk). J Biol Chem 1998,
273:13217-13222.
8. Ghose R, Shekhtman A, Goger MJ, Ji H, Cowburn D: A novel, specific
interaction involving the Csk SH3 domain and its natural ligand. Nat
Struct Biol 2001, 8:998-1004.
9. Cloutier JF, Veillette A: Cooperative inhibition of T-cell antigen receptor
signaling by a complex between a kinase and a phosphatase. J Exp Med
1999, 189:111-121.
10. Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T:
Characterization of TCR-induced receptor-proximal signaling events
negatively regulated by the protein tyrosine phosphatase PEP. Eur J
Immunol 1999, 29:3845-3854.
11. Wu J, Katrekar A, Honigberg LA, Smith AM, Conn MT, Tang J, Jeffery D,
Mortara K, Sampang J, Williams SR, Buggy J, Clark JM: Identification of
substrates of human protein-tyrosine phosphatase PTPN22. J Biol Chem
2006, 281:11002-11010.
12. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M,
MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS,
Comings D, Mustelin T: A functional variant of lymphoid tyrosine
phosphatase is associated with type I diabetes. Nat Genet 2004,
36:337-338.
13. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE,
Chang M, Ramos P, Baechler EC, Batliwalla FM, Novitzke J, Williams AH,
Gillett C, Rodine P, Graham RR, Ardlie KG, Gaffney PM, Moser KL, Petri M,
Begovich AB, Gregersen PK, Behrens TW: Genetic association of the
R620W polymorphism of protein tyrosine phosphatase PTPN22 with
human SLE. Am J Hum Genet 2004, 75:504-507.
14. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP,
Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT,
Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE,
McAllister LB, Jeffery DA, Lee AT, Batliwalla F, Remmers E, Criswell LA,
Seldin MF, Kastner DL, Amos CI, Sninsky JJ, Gregersen PK: A missense
single-nucleotide polymorphism in a gene encoding a protein tyrosine
phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum
Genet 2004, 75:330-337.
Wang et al. BMC Molecular Biology 2010, 11:78
http://www.biomedcentral.com/1471-2199/11/78
Page 6 of 715. Carlton VE, Hu X, Chokkalingam AP, Schrodi SJ, Brandon R, Alexander HC,
Chang M, Catanese JJ, Leong DU, Ardlie KG, Kastner DL, Seldin MF,
Criswell LA, Gregersen PK, Beasley E, Thomson G, Amos CI, Begovich AB:
PTPN22 genetic variation: evidence for multiple variants associated with
rheumatoid arthritis. Am J Hum Genet 2005, 77:567-581.
16. Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JM,
Vella A, Nutland S, Rance HE, Maier L, Barratt BJ, Guja C, Ionescu-
Tîrgoviste C, Savage DA, Dunger DB, Widmer B, Strachan DP, Ring SM,
Walker N, Clayton DG, Twells RC, Gough SC, Todd JA: Replication of an
association between the lymphoid tyrosine phosphatase locus (LYP/
PTPN22) with type 1 diabetes, and evidence for its role as a general
autoimmunity locus. Diabetes 2004, 53:3020-3023.
17. Vang T, Congia M, Macis MD, Musumeci L, Orrú V, Zavattari P, Nika K,
Tautz L, Taskén K, Cucca F, Mustelin T, Bottini N: Autoimmune-associated
lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet
2005, 37:1317-1319.
18. Chien W, Tidow N, Williamson EA, Shih LY, Krug U, Kettenbach A,
Fermin AC, Roifman CM, Koeffler HP: Characterization of a myeloid
tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction
pathway. J Biol Chem 2003, 278:27413-27420.
19. Ben-Dov C, Hartmann B, Lundgren J, Valcárcel J: Genome-wide analysis of
alternative pre-mRNA splicing. J Biol Chem 2008, 283:1229-1233.
20. Licatalosi DD, Darnell RB: RNA processing and its regulation: global
insights into biological networks. Nat Rev Genet 2010, 11:75-87.
21. Wang D, Sadée W: Searching for polymorphisms that affect gene
expression and mRNA processing: example ABCB1 (MDR1). AAPS J 2006,
8:E515-20.
doi:10.1186/1471-2199-11-78
Cite this article as: Wang et al.: Identification of a variant form of
tyrosine phosphatase LYP. BMC Molecular Biology 2010 11:78.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wang et al. BMC Molecular Biology 2010, 11:78
http://www.biomedcentral.com/1471-2199/11/78
Page 7 of 7